



January 01, 2026

To,
Listing/ Compliance Department
BSE LTD.
Pheroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

**Sub.: Appointment of Senior Management Personnel of
the Company**
**Re.: Regulation 30 of the Securities and Exchange
Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 ('Listing
Regulations')**

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, we hereby inform that the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee has approved the appointment of Dr. Rakeshwar Bandichhor as Chief Scientific Officer – R&D (Research and Development) and Senior Management Personnel of the Company effective January 01, 2026

The requisite disclosure under Regulation 30 of the Listing Regulations read with Para A of Part A of Schedule III to the Listing Regulations and SEBI Circular Ref. No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure I.

The above information is also available on the website of the Company: www.aartipharmalabs.com

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

**JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565**

Encl: a/a

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Information as required under Regulation 30 - Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Annexure I

Sr. No.	Particulars	Description
	Name	Dr. Rakeshwar Bandichhor
1	Reason for change in Senior Management Personnel	Appointment as Chief Scientific Officer – R&D (Research and Development) and Senior Management Personnel of the Company
2	Date of Appointment	January 01, 2026
3	Brief Profile	Dr. Rakeshwar Bandichhor brings with him 25 years of rich experience in API-R&D and Process Chemistry. He holds a M.Sc. (Chemistry) & M.Sc. (Tech) in Pharmaceutical Chemistry from University of Lucknow, Ph.D. in Chemistry, CDRI, University of Lucknow and University of Regensburg Germany through a German fellowship program. Thereafter, he has gone through three intensive postdoctoral trainings at University of Regensburg, Germany, University of Pennsylvania, USA, and Texas A&M University, College Station, USA. Prior to this appointment, he was associated with Dr. Reddy's Laboratories in Hyderabad.
4	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable